S1C2 :Prescription Drug Product Submissions

原文始发于微信公众号(化学音乐文化):S1C2 :Prescription Drug Product Submissions

S1C2 :Prescription Drug Product Submissions

JanFourman,PhD, EdD,MBA, MSRA

S1C2 :Prescription Drug Product Submissions

Eli Lilly – Pharma registration for diabetes/endocrine, women/men’s health, neural science, oncology, bone/muscle/joint therapeutic areas – 5 years
Eli Lilly – Pharmacovigilance – 7 years
Eli Lilly – Regulatory Intelligence – 3 Years
Purdue University and Roche Diagnostics – Teaching global pharma development, Africa and US
Consultant for Indiana Technical Assistance Program
Invited conference speaker
Published author

S1C2 :Prescription Drug Product Submissions
S1C2 :Prescription Drug Product Submissions


Prescription Drug Product Submissions

What is an Investigational New Drug (IND) application?

How to Organize the IND:

Electronic Common Technical Document (eCTD) – Focus on Module 2

Target Product Profile (TPP)

Submission Strategies:

New Chemical Entities (NCEs)

Fast Track Designation

Breakthrough Therapy Designation

Accelerated Approval

Priority Review Voucher

Orphan Drug Designation


打赏 为好文打赏 支持药时代 共创新未来! 为好文打赏 支持药时代 共创新未来!
上一篇 2020年2月18日 00:00
下一篇 2020年2月18日 12:25